Form 8-K IDEAYA Biosciences, Inc. For: Apr 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Ideaya Biosciences (IDYA) PT Raised to $52 at Mizuho, 'we recommend being opportunistic'
April 13, 2026 3:08 PM EDTMizuho analyst Graig Suvannavejh raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $52.00 (from $46.00) while maintaining a Outperform rating.
The analyst comments "Following up on Quick Take comments earlier today (LINK) on positive P2/3 data for darovasertib/daro (a protein kinase C/PKC... More
Ideaya Biosciences (IDYA) PT Raised to $65 at Truist Securities
April 13, 2026 2:05 PM EDTTruist Securities analyst Greg Renza raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $65.00 (from $60.00) while maintaining a Buy rating.
The analyst comments "Today's disclosure highlights daro's best-in-class PFS and consistent efficacy to an earlier study which together with a favorable OS trend... More
